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Drug Eluting Stent (DES) in the treatment of Peripheral Arterial Disease in lower 
limbs in Colombia. Methods: An analytical decision model was considered with 
Target Lesion Restenosis (TLR) avoided and total cost at the end of a two year period 
as endpoints. An Excel model was developed. For the effectiveness data a Meta-
analysis was done and second revascularization procedures probabilities were taken 
with KOL criterion. A public payer perspective was assumed. Total costs were taken 
from reimbursement values charged to payers. Because effectiveness and cost were 
taken as unique values at the end of the two years with no cycles, discount rate 
was no applied. The sensitivity Univariate analysis was done for DEB vs. PTA. For 
the Probabilistic Sensitivity Analysis a Monte Carlo Simulation with 1000 iterations 
was done. Results: TLR Avoided probability with DEB was 0.86 vs. 0.60, 0.72 and 
0.81 for PTA, BMS and DES respectively. DEB total cost was US$4.441 vs. US$3.893 for 
PTA, US$4.826 for BMS and US$5.599 for DES. Respect to PTA, DEB ICER was US$2.142, 
US$7.776 for BMS and US$8.204 for DES. In univariate sensitivity the DEB ICER was 
especially sensible to total costs for both therapies and for the TLR probability for 
PTA. The Willingness-To-Pay (WTP) acceptability curves show that DEB, compared to 
other therapies, had a higher probability to be accepted for all the WTP values above 
US$2.500, reaching a probability of 94% for US$10.000 WTP value ConClusions: 
DEB have better cost-effectiveness ratio than PTA, with an ICER of US$2.142 and 
was dominant over BMS and DES. The univariate sensitivity analysis shows the 
ICER of DEB vs. PTA was especially sensible to the total costs of the therapies and 
the effectiveness of PTA.
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objeCtives: To fill the knowledge gap of cost-effectiveness result between rand-
omized clinical trials and real world practice in treating patients with medically 
managed severe aortic stenosis, a hybrid comparison model, using a US societal 
perspective, was conducted. Methods: The cost-effectiveness of Transcatheter 
Aortic Valve Replacement (TAVR) was compared to medical management using the 
2010 PARTNER trial (Cohort B) result and 2003 Medicare claims analysis (compari-
son group) on a population with severe aortic stenosis (AS). Survival rate, quality of 
life , medical resource use and related hospital and physician cost were reported 
in the PARTNER trial. The Medicare claims analysis presented survival rate and 
overall cost in treating severe AS, which was converted to 2010 dollars. To calculate 
quality-adjusted life expectancy, and estimate the incremental cost-effectiveness, 
QALY for Medicare claims analysis was derived from the control arm of PARTNER 
trial. The effect of uncertainty in model parameters was examined through one 
way sensitivity analysis and probabilistic sensitivity analysis (PSA). Results: 
Over a two-year time horizon, in the base case the cost of TAVR was higher than 
the comparison group by $65,813. An additional 0.5 quality-adjusted life years 
was gained in the TAVR group. The resultant incremental cost-effectiveness ratio 
(ICER) was $ 132,155 per QALY gained for patients treated with TAVR vs. managed 
medically. Given $150,000 as the acceptability threshold for ICER willingness to pay, 
66.4% iterations in PSA were favorable toward TAVR. ConClusions: In real world 
practice where it is difficult to qualify patients with rigid criteria, our result shows 
that TAVR fell at the borderline of the cost effectiveness acceptability threshold. 
Although this study only considers the first two years of treatment, given the 
relatively short 2-3 year life expectancy of medically managed patients with severe 
AS, this result highlights the importance to have a strict guideline for TAVR to 
ensure its cost effectiveness.
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objeCtives: Familial hypercholesterolemia (FH) is a genetic disease that causes 
build-up of low-density lipoprotein cholesterol and premature coronary heart dis-
ease. Taken regularly, statins can lower cholesterol and risk of heart attack and 
stroke in FH individuals and high cholesterol individuals with no FH gene mutations. 
However, the US FH diagnosis rate is only 20% of actual cases, and patients gener-
ally have suboptimal statin adherence. Given cost-effectiveness studies evaluating 
genetic screening for FH in Europe, similar screening strategies with adherence 
programs could be cost-effective in the US. The objective of this study is to conduct 
a cost-effectiveness analysis of lipid cascade screening, genetic cascade screen-
ing, and lipid cascade screening plus statin adherence program for FH diagnosis 
and treatment in terms of incremental cost-effectiveness ratios (ICERs) between 
strategies. Methods: A Markov model with transition probabilities derived from 
published literature was used to model screening strategies. Because the model 
assumes an initial cohort of high cholesterol adults with a family history of FH, lipid 
cascade screening is the base case. US costs and quality of life data were obtained 
from published literature and public data. Results: Genetic cascade screening is 
dominated by base case screening, with an ICER of $532,222/QALY between the two. 
While the lifetime costs of statin adherence programs exceed the onetime costs 
of genetic testing, lipid cascade screening with statin adherence program is the 
most cost-effective strategy with an ICER of $10,705/QALY compared to the base 
case. At a US willingness-to-pay of $150,000/QALY, net monetary benefit analysis 
suggests that genetic cascade screening will only produce non-negative benefits 
at screening costs of less than $1,700 per diagnosed case. ConClusions: Genetic 
cascade screening for FH is not cost-effective in a US setting. The addition of statin 
adherence programs is cost-effective, but lack of US FH studies suggests a need for 
further analyses.
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objeCtives: The objectives were to compare the effectiveness and cost-effectivness 
of carotid artery stent with emboli protection device (CAS+EPD) and carotid endar-
terectomy (CEA). Methods: A retrospective cohort during 2001-2012 was built 
using NHI database. Outcomes events cumulative incidence rate of death, stroke, 
death or stroke, and MI occurring 30 days peri-procedure, 1 year and 8 years after 
procedure, were analyzed as comparative effectiveness. The transitional probabili-
ties of various outcomes were adopted from comparative effectiveness results by 
Weibull distribution. Kaplan Meier sample average method was applied for medical 
cost. A Markov model was built to simulate the lifetime QALYs and medical costs 
estimation. Results: A total of 3,359 and 543 patients were included in CAS+EPD 
and CEA groups. In comparative effectiveness, the incidences of safety outcomes 
in stroke (2.2% vs. 2.0%), death (0.7% vs. 1.5%), and death or stroke (2.7% vs. 2.9%) 
did not differ significantly between CAS+EPD and CEA within 30 days post proce-
dure. A one-year follow-up revealed that CEA was associated with higher risks of 
stroke (hazard ratio: 2.72, 95%CI: 1.61-4.61) and death or stroke (HR: 2.00, 95%CI: 
1.33-3.02) than CAS+EPD. Long term follow-up results demonstrated CEA had a 
higher risk in stroke (HR: 1.61, 95%CI: 1.09-2.37) only. The hospitalization cost were 
$5,600±2,500 in CAS+EPD and $ 4,800±6,100 in CEA, the total medical expense during 
the first year were $11,600 and $10,000, respectively. Life-long medical cost estima-
tion revealed $28,700 for CAS+EPD and $31,300 for CEA. Cost-effectiveness analysis 
showed CAS+EPD had 0.59 life years (LYs) gained better than CEA (9.24 LYs vs. 8.65 
LYs). The QALYs for CAS+EPD and CEA were 8.12 and 6.99, respectively. Overall, 
the results demonstrated CAS+EPD to be the dominant strategy. ConClusions: 
Retrospective cohort database analysis demonstrated CAS+EPD was more effective 
and also less expensive than CEA. Under current NHI reimbursement, the CAS+EPD 
was a cost-effective strategy.
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objeCtives: Warfarin has been the standard oral anticoagulant for stroke preven-
tion in patients with atrial fibrillation (AF). However, it has an increased risk of 
bleeding and a narrow therapeutic range which required frequent monitoring of the 
International Normalized Ratio (INR) and dose adjustments. Dabigatran, a novel oral 
anticoagulant, has demonstrated to be at least as effective and as safe as warfarin, 
and shown to be cost-effective in Canada and UK. Recently, dabigatran received 
approval in China. In this study, we aim to assess the potential cost-effectiveness 
of dabigatran for the prevention of stroke and systemic embolism among patients 
with AF as compared to warfarin as a first-line therapy, from the payer perspec-
tive in China. Methods: An individual level simulation model was developed to 
simulate the clinical events and outcomes under different treatment pathways over 
a patient’s remaining lifetime. The model explicitly incorporated an INR control 
component to account for heterogeneous use of warfarin in different populations 
and in settings. Input data were derived from the published literature, NICE STA 
reports, and expert inputs. Patient baseline profiles were based on China Registry 
of AF (CRAF), a multicenter, cross-sectional study of 3551 AF patients in mainland 
China. Results: Comparing to warfarin first-line use among patients eligible for 
anticoagulants, dabigatran was associated with 0.40 fewer ischemic stroke, 0.11 
fewer systemic embolism, 0.19 fewer hemorrhagic stroke, 0.30 fewer intracranial 
hemorrhage, 1.33 more extra-cranial hemorrhage and 0.38 more acute myocardial 
infarction, per 100 patient-year. Predicted incremental costs and QALYs are US$ 
13527.88 and 0.23, respectively, resulting an ICER of US$ 59546.08 per QALY gained. 
The result was sensitive to the cost of dabigatran cost, warfarin-related cost, and INR 
control assumptions. ConClusions: The cost-effectiveness of new anticoagulation 
therapy should be considered when making treatment recommendations. Further 
economic evaluation of appropriate use of dabigatran in China setting is needed.
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objeCtives: Cost-Effectiveness analysis of Minimally Invasive Cardiac Surgery 
(MICS) vs. Conventional Approach (CA) for surgical valve replacement in 
Colombia. Methods: An analytical decision model was considered with any imme-
diate severe complication avoided and total cost at the end of the hospitalization as 
the endpoint results. A deterministic and probabilistic Excel model was developed. 
Complications rates and costs were taking from 240 registries in a period of time 
between 01-2010 and 10-2012, from Cardiovascular Clinic Cardiovid at Medellin 
Colombia. Colombian Health System payer perspective was assumed and reim-
bursement prices were considered as the final costs for the procedures, including 
those until hospital discharge. Because only one cycle was considered there was no 
need to apply a discount rate. The deterministic ICER calculations analysis was done 
including a univariate sensitivity analysis. For the Probabilistic Sensitivity Analysis a 
Monte Carlo Simulation with 1000 iterations was done. Results: The complications 
avoided probability with MICS was 0.73 compared to 0.57 with CA. The total cost 
was US$14.330 for MICS compared to US$ 13.006 for CA with an ICER of US$ 8.326 
